Mandate

Vinge advises Procuritas on its acquisition of We Select

Vinge advises Procuritas Capital Investors in connection with its acquisition of a majority stake in The We Select Company AB (“We Select”), a fast-growing digital talent acquisition platform. Key management will retain significant ownership of the company after the transaction.

We Select was founded in 2011 as a traditional recruitment services company. After launching its digital talent attraction offering in 2016, the company quickly transformed its business model and focused entirely on the fast-growing talent acquisition segment – social media. We Select helps companies to attract and hire top talent easily by combining strategic employer branding, data-driven job advertising and automatic candidate management in one smart platform.

Vinge’s team mainly consisted of Jonas Johansson, Carl Sander, Linus Adolfsson (M&A), Seyran Sahin, Karl-Gustaw Tobola (Banking and Finance), Elin Broman (Employment), Arvid Axelryd, Anna Högsten (IP), Lisa Hörnqvist (IT & GDPR), Kristoffer Sällfors (Public Procurement) and Anna Ekdahl Roos (Project Assistant).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025